USNA (61) SNDL (61) ACB (58) OBIO (28) ⌘ Pro Terminal →

Canopy Growth Corporation (CGC) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell CGC stock right now?

Canopy Growth Corporation (CGC) currently earns a Roarable Rating of D (Sell — SELL) with 51/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

Q: What is CGC's 12-month price target and RQD AI Jury consensus?

CGC's 12-month base price target is $0.66 (range $0.51 to $2.5), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$0.68 +0.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.68

Canopy Growth Corporation (CGC) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY) →

ROARABLE D • SELL / AVOID Cap $285.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.68 (-0.11%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 0.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-2.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CGC)Realized 20D OHLCV Swing Band: ±12.3%

Deterministic 5-Pillar Attribution (51/100 Composite)

🔍 WHY CGC SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.3% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+11/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0.2% FCF Margin ($8.0M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution7/20 pts (-13 pt drag)

Disciplined Float (+0.16% YoY Shares) & executive Form 4 sales trim 13 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$0.83-14.5% Next Q

Q2 (-2Q)

Grade C$0.71-4.2% Next Q

Q3 (-1Q)

Grade C-$0.68+0% Next Q

Current

Grade D$0.68-1.3% Hist 90D α

Trajectory: C (59) → D (51)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CGC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CGC currently carries a cautious 51/100 (D) rating due to Insider Conviction & Share Dilution (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.87) and Max Pain ($0.71) forces dealer call-delta covering toward $2.50.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CGC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CGC Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 51%NO 49%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

24.930 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

1 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $1$0.68H: $2

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: D+RQD 11 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 20 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on CGC

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (55)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (50)

20/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like CGC

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CGC)

✓Walkthrough of CGC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CGC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -38.74%▼ DESCENDING CHANNEL

2026-10-30O $0.69H $0.69L $0.64C $0.68VOL 2.28M

RES: $1.03SUP: $0.61SMA50: $0.87SMA200: $1.00

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CGC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CGC Butterfly Map → + Track CGC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CGC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CGC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CGC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CGC)

Health Care Rank #335 of 1016 ⚔️ USNA vs CGC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CGC vs. USNA, SNDL, ACB, OBIO)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Canopy Growth Corporation (CGC) ranks #335 by composite RQD confidence (51/100, grade D) and #526 by equity capitalization ($285.6M). Within this direct 5-issuer industry benchmark cohort, USNA leads on earnings valuation at 24.6x trailing P/E, while USNA leads on capital efficiency and profitability with 7.9% ROIC and 78.3% gross margin. USNA currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with CGC at 51/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CGC ACTIVE Canopy Growth Corporation	D	51/100	—	—	—	+0.46%	$285.6M	Benchmark Subject
USNA USANA Health Sciences Inc.	C-	61/100	24.6x	78.3%	7.9%	-1.91%	$265.0M	/usna-vs-cgc →
SNDL SNDL Inc.	C-	61/100	—	—	—	+0.78%	$316.3M	/sndl-vs-cgc →
ACB Aurora Cannabis Inc.	D+	58/100	—	—	—	0.00%	$252.8M	/acb-vs-cgc →
OBIO Orchestra BioMed Holdings Inc.	E	28/100	—	96.0%	-35.0%	+1.67%	$366.0M	/obio-vs-cgc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001737927

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Canopy Growth Corporation (CGC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$189.0M, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, CGC closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-31	$0	-$189.0M	—	—	—	—
FY2024 (FY)	2025-03-31	$0	-$354.0M	—	—	—	—
FY2023 (FY)	2024-03-31	$0	-$526.0M	—	—	—	—

3. CGC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CGC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Canopy Growth Corporation (NASDAQ: CGC) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $0.68 (+0.46% 1D, market cap $285.6M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, CGC ranks #335 in composite RQD confidence.

How does CGC compare to USNA and SNDL in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), CGC carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, USNA (USANA Health Sciences Inc.) holds a C- grade (61/100 RQD, P/E 24.6x, ROIC 7.9%, cap $265.0M) and SNDL (SNDL Inc.) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $316.3M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CGC?

Per CGC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001737927), Canopy Growth Corporation generated $0 in revenue, -$189.0M in net income, and $0 in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CGC trading relative to its 50-day, 200-day, and 52-week technical levels?

CGC last traded at $0.68 (+0.46% on volume of 1,131,833 shares), positioning the stock -21.84% below its 50-day simple moving average ($0.87) and -32.00% below its 200-day simple moving average ($1.00). Across its 52-week range of $0.64 to $2.38, CGC sits at the 2.3% percentile with a 14-day RSI of 24.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.3% ($1.00 to $0.76).

CGC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CGC stock right now?

Canopy Growth Corporation (CGC) currently earns a Roarable Rating of D (Sell — SELL) with 51/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is CGC's 12-month price target and RQD AI Jury consensus?

CGC's 12-month base price target is $0.66 (range $0.51 to $2.5), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: CGC RQD Cockpit CGC 12M Forecast CGC Earnings & Move CGC Dividends & DRIP CGC Insiders & 13F CGC Whale Options CGC Profit Sankey CGC News & Why